Day: April 9, 2025

TEL AVIV, Israel, April 09, 2025 (GLOBE NEWSWIRE) — Xylo Technologies Ltd. (Nasdaq: XYLO) (“Xylo” or the “Company”), a technology-based company engaged in advanced innovative technologies, announced today that Revoltz Ltd. (“Revoltz”), which is 19.9% held by Charging Robotics, Inc. (OTC: CHEV) (“Charging Robotics”), a Delaware corporation quoted on the OTC Market (62.22% owned by Xylo), has been named a winner of the TAIPEI CYCLE d&i awards 2025, one of the most respected international honors for innovation and design in the bicycle and micro-mobility sector. Revoltz was selected in the Micro-Mobility category, standing out among more than 150 submissions from 11 countries. The award recognizes Revoltz’s unique approach to sustainable last-mile mobility, with the jury—composed of globally renowned designers and industry experts—commending...

SOUTH SAN FRANSCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces its first clinical trial site for the Company’s Phase 1 clinical trial of CER-1236.  The trial is focused on patients with acute myeloid leukemia (AML), and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025. The trial will be led by Abhishek Maiti, M.D., assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center. The first-in-human, multi-center, open label, Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with...

LONG BEACH, Calif. and TORONTO, April 09, 2025 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in the U.S., today announced a collaboration with the University of California, Berkeley, to explore hemp-related research, including novel medicinal product development, identification and improvement of hemp genetics, market analysis, supply chain sustainability, and AI automation for cultivation and production. In addition, the collaboration aims to evaluate data-driven and evidence-based approaches to hemp policy and regulation, with the aim of reducing uncertainty for California hemp growers. This collaboration will explore potential drug development...

Truth+ Apps Can Be Downloaded North and South of the Border SARASOTA, Fla., April 09, 2025 (GLOBE NEWSWIRE) — Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: DJT) (“TMTG” or “the Company”), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, has launched its Truth+ TV streaming app and connected TV apps in Canada and Mexico. The Truth+ mobile app is now available throughout Canada and Mexico in the Apple App Store for iOS devices and the Google Play Store for Android devices. Truth+ connected TV apps are available in the relevant app stores for Roku, Apple, Android, and Amazon Fire TVs. TMTG CEO and Chairman Devin Nunes said, “Truth Social and Truth+ are now fully open for business in Canda and Mexico. We hope our northern and...

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine’s REAL Space, the world’s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized compounds designed to accelerate drug discovery against 100 key and clinically relevant drug targets in difficult to address biological areas. Enamine’s REAL Space represents the continuously expanding chemical library built on insights from millions of parallel syntheses. While the chemical space offers incredible potential, the sheer...

CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market Worldwide Non-Dilutive Funding Expands Pipeline and Further Validates Cingulate’s Proprietary Precision Timed Release™ Drug Delivery Technology CTx-2103 has the Potential to Reduce Use of Benzodiazepine’s and Associated Withdrawal and Dependency Issues KANSAS CITY, Kan., April 09, 2025 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has received a $3 million grant to accelerate the development...

FREMONT, Calif., April 09, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced the launch of its most powerful and versatile battery yet, the IQ® Battery 5P with FlexPhase, for customers in Poland. The IQ Battery 5P with FlexPhase is an all-in-one AC-coupled system that delivers reliable backup power and supports both single-phase and three-phase applications, providing superior flexibility to meet diverse home energy needs. Enphase recently launched the FlexPhase battery in Germany, Austria, Switzerland, and Luxembourg. The IQ Battery 5P starts at 5 kWh of capacity and multiple units can be configured to provide up to 70 kWh. Each 5 kWh battery is designed to deliver continuous power...

NDA Submission Anticipated Q2 Calendar 2025 PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced details of the Company’s Type C meeting with the U.S. Food and Drug Administration (FDA). The purpose of this meeting was to obtain FDA feedback on the completed Phase 3 STRIVE-ON safety trial of GTx-104 and its planned New Drug Application (NDA) submission including clinical, non-clinical, and chemistry, manufacturing, and control (CMC) requirements. Based on feedback from the FDA, the Company believes that...